During the Early Pre-Launch Phase (see Blog entry 5 for a breakdown of phases), while the overall pharma launch strategy is being developed, one of the key items is whether or not a Reimbursement Hub is appropriate or necessary for your orphan drug or specialty pharmaceutical product. As described in an earlier post, using our trademarked BCSDS – the BioSolutia Commercialization Strategy Development System, will help determine the answer to this question – is a Reimbursement Service Hub needed for my product? The answer is based on a critical review of the needs of the 5 key stakeholders and the 15 key characteristics of your orphan drug or specialty pharmaceutical product.
In a situation where a Reimbursement Hub is indicated or even required due to various product characteristics, this is also the time where data needs in addition to reimbursement hub services design should also be determined. We’ll talk about data needs in a future post (see blog entry 7).
Reimbursement Hub Services needs and design should be a function of:
Products Characteristics: For example:
So overall, you can easily see there are many potential areas where a Reimbursement Services Hub can impact the success of your orphan or specialty pharmaceuticals drug launch.
A new era in specialty pharmacy – Higher priced meds will require high-touch care, a role that the Reimbursement Hub plays.
Numerous clients come to BioSolutia’s pharma consulting practice looking to duplicate what another product has done in terms of their pharma launch strategy eg. reimbursement support services (hub), specialty pharmacy distribution, patient assistance programs, clinical support services, etc. The issue is every pharma launch or product commercialization situation is different and requires a uniquely customized strategy. That’s where BioSolutia’s specialty pharmaceutical consulting services are different. Our expertise lies in having done over 50 pharma launches and re-launches of some of the most unique and successful products in the marketplace. You wouldn’t ask a surgeon to “just do the same thing you did on your last patient” so why would you take a “copycat” approach to your pharma launch strategy. When selecting a firm to provide pharma consulting or specialty pharmaceutical consulting, experience and the ability to develop a strategy specific for your product’s needs in your specific market situation is the key to success. That’s the BioSolutia difference.